---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032412"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:14:07.958729+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q1 FY2025 revenue up 109% YoY to $18.8M; operating profit +144%

## Summary
- Revenue of $18.8M for Q1 ended June 30, 2024, compared to $9.0M in Q1 FY2024.
- Operating profit rose to $3.9M from $1.6M YoY, a 144% increase.
- Net income attributable to common shareholders was $0.6M.
- Growth driven by higher sales of Elite label product line.
- Conference call scheduled for August 15, 2024 at 11:30 AM EDT.

## SEC filing metadata
- accession: 0001493152-24-032412
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224032412/0001493152-24-032412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224032412/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032412
- JSON: https://secwatch.observer/filing/0001493152-24-032412.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.